SARS News and Research

RSS

Two repurposed drugs and a blue dye show potential as SARS-CoV-2 entry inhibitors

A new multidisciplinary study from Australia, published in the open-access journal mBio, shows that three compounds used to treat cystic fibrosis, dry eye, and a specific medical dye may lead to future strategies for the treatment of coronavirus disease (COVID-19).

25 Apr 2021

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Researchers in the UK have shown that a single dose of the Pfizer-BioNTech vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced antibody and cellular responses in patients with chronic myeloid leukemia (CML) who were taking tyrosine kinase inhibitors.

25 Apr 2021

Pfizer-BioNTech COVID-19 vaccine shows real-world efficacy, despite the circulation of B.1.1.7 variant

Researchers in the UK have conducted a study showing the real-world effectiveness of Pfizer-BioNTech’s vaccine at protecting against symptomatic coronavirus disease 2019 (COVID-19) when it is administered in line with the original dosing schedule.

25 Apr 2021

High dose of vitamin D does not have a beneficial effect on moderate or severe COVID-19 patients

Can a high dose of vitamin D administered on admission to hospital improve the condition of patients with moderate or severe COVID-19? The answer is no, according to a Brazilian study published in the Journal of the American Medical Association.

23 Apr 2021

FDA, CDC lift recommended pause on the use of Janssen COVID-19 vaccine in the U.S.

Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

23 Apr 2021

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

23 Apr 2021

The Native Antigen Company Launches SARS-CoV-2 Neutralisation Assay Development Kit

The Native Antigen Company today announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit.

From The Native Antigen Company 23 Apr 2021

Researchers identify natural molecule that blocks the binding of human antibodies to SARS-CoV-2

Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus.

23 Apr 2021

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen.

23 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Artificial intelligence helps identify new key-lock pairs against coronavirus

The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them.

23 Apr 2021

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

A team of scientists from the United States has recently compared the immune response elicited by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Their findings reveal that, unlike vaccination, natural SARS-CoV-2 infection is associated with a robust interferon response together with an induction of cytotoxic gene expression in peripheral blood lymphocytes. The study is currently available on the medRxiv* preprint server.

22 Apr 2021

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Researchers in the United States have shown that the antibody response induced by the Moderna mRNA-1273 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a correlate of immune protection against coronavirus disease 2019 (COVID-19) in non-human primates.

22 Apr 2021

Slow COVID-19 vaccine rollout in Tokyo could mean no Olympic and Paralympic Games

Researchers in Japan have warned that Tokyo's Olympic and Paralympic Games, which is set to start in July 2021, may need canceling if the rollout of vaccination to protect against coronavirus disease 2019 (COVID-19) continues at the slow pace it is now.

22 Apr 2021

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.

22 Apr 2021

House flies can carry SARS-CoV-2 up to 24 hours after exposure, study finds

A team of researchers in the USA – at Kansas State University and Agricultural Research Service – found that house flies can acquire and harbor infectious SARS-CoV-2 for up to 24 hours after exposure.

22 Apr 2021

Can SARS-CoV-2 host factor protein interactions help identify antiviral drug targets?

In a new study proteomic peptide-phage display is utilized to profile the novel SLiM-based interactions that mediate host factor interactions in 229 RNA viruses, with a special focus on SARS-CoV-2, to reveal mechanistic insights and identify drug targets.

22 Apr 2021

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.

22 Apr 2021

Pre-Clinical Vaccine Adjuvant and Therapeutics Manufacturing

Analytik reports how its Microfluidizer® processors are enabling researchers develop a range of therapeutic formulations including vaccine adjuvants, liposomes and lipid nanoparticles.

From Analytik Ltd 22 Apr 2021

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

New research has been released, which focuses on the transmission and prevalence of SARS-CoV-2 in New Zealand, through a blood donor serosurvey.

22 Apr 2021

SARS News and Research

Two repurposed drugs and a blue dye show potential as SARS-CoV-2 entry inhibitors

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Pfizer-BioNTech COVID-19 vaccine shows real-world efficacy, despite the circulation of B.1.1.7 variant

High dose of vitamin D does not have a beneficial effect on moderate or severe COVID-19 patients

FDA, CDC lift recommended pause on the use of Janssen COVID-19 vaccine in the U.S.

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

The Native Antigen Company Launches SARS-CoV-2 Neutralisation Assay Development Kit

Researchers identify natural molecule that blocks the binding of human antibodies to SARS-CoV-2

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

Celastrol shows potential anti-SARS-CoV-2 activity

Artificial intelligence helps identify new key-lock pairs against coronavirus

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Slow COVID-19 vaccine rollout in Tokyo could mean no Olympic and Paralympic Games

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

House flies can carry SARS-CoV-2 up to 24 hours after exposure, study finds

Can SARS-CoV-2 host factor protein interactions help identify antiviral drug targets?

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Pre-Clinical Vaccine Adjuvant and Therapeutics Manufacturing

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News